Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
PHASE1CompletedINTERVENTIONAL
Enrollment
15
Participants
Timeline
Start Date
February 28, 1998
Study Completion Date
April 30, 2000
Conditions
VasculitisWegener's Granulomatosis
Interventions
DRUG
Interleukin-10
Trial Locations (1)
20892
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00001761 - Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis | Biotech Hunter | Biotech Hunter